Lilly wins approval for potential blockbuster drug
The Indianapolis-based pharmaceutical maker gets a much-needed boost with FDA approval for gastric-cancer drug ramucirumab, which quickly could account for $1 billion in annual sales.
Life Science & Biotech
Articles
In Indiana, everyone makes big profits on health care
Indiana is the most profitable state for Indianapolis-based WellPoint Inc., which operates Blue Cross and Blue Shield health plans in 14 states. WellPoint’s margin for Indiana in 2012 was 5.8 percent, 38 percent higher than WellPoint’s national average.
Indiana’s 10 (or more) most profitable health insurers
WellPoint’s commanding market share gave it a whopping $129 million in profit from its risk-based insurance products in 2012. But in percentage terms, WellPoint was not at the top of the heap.
Competition, not higher premiums, is biggest threat to Obamacare buyers
For consumers that get tax subsidies in the Obamacare exchanges, out-of-pocket premiums will remain steady even if insurers raise prices next year. But the subsidies could fall if insurers offer lower-cost plans.
Five things I learned from the Medicare doctor payments
From this week’s historic data dump, I learned who the top 20 recipients of Medicare payments are in Indianapolis (hint: mostly labs, ambulances and eye surgeons). But the real takeaway is that meaningful price information about doctors is still a long way away.
Lilly shares hit all-time high for the John Lechleiter era
Court win last week in a patent challenge to lung cancer drug Alimta pushed Lilly shares higher than they’ve ever been since April 2007. Since then, the company’s pipeline has produced more misfires than the villains in a James Bond movie
Endocyte raises another $100M in stock offering
Another public stock offering by the West Lafayette-based drugmaker swells its war chest for cancer drug development to $225 million.
The Millionaire Doctors Club
The scramble for physicians by hospitals in recent years has led to more than a dozen physicians cracking a million dollars in compensation—and three dozen receiving at least a half million dollars. Hospitals, meanwhile, are recording big losses on their physician practices.
Do double-digit Obamacare rate hikes mean the law has failed? No, but …
For now, at least, the year-to-year price increases of individual insurance under Obamacare look a lot like they did before Obamacare. That’s not a failure, but it’s not a success either.
Dow Agro parent sets stage for sale or spinoff
Dow AgroSciences LLC is likely to become a stand-alone public company in the next three years, according to some Wall Street analysts—if the wunderkind division of Dow Chemical Co. lives up to sky-high expectations.
Where do hospital profits go?
When patients at Indianapolis-area hospitals pay their bills, they're not just funding their own health care. They're contributing to the care of Hoosiers in the rest of the state, too, especially care provided by hospital-employed physicians.
Medic! Early signal shows hospital profits plunged in 2013
Franciscan Alliance, always the first to report its year-end financial results, put out numbers that show a real decline in profit from operations of 58 percent.
Endocyte stock doubles after key approval in Europe
The stock price of Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.
Dow Agro CEO retiring as divesture speculation returns
Dow AgroSciences is getting a new chief, the company said Friday. Meanwhile, the CEO of parent company Dow Chemical says Dow Agro could be sold off in a year or two.
Top 10 most profitable hospitals around Indianapolis
Based on 2012 data, 23 of 30 hospitals in central Indiana are generating profits from their operations of 10 percent or more. The Indiana Orthopaedic Hospital and St. Vincent's Carmel campus are on top. After that, there are a few surprises.
Can we, please, get a better name than ‘accountable care’?
Health care is going through dramatic change—but is doing so under some of the dullest names possible. So I’m offering a few alternatives that are more to the point. How about, ‘No-more-bankruptcy care’?
Biomet plans $40.5 million upgrade, 150 jobs
Biomet’s project calls for building renovations and adding 3-D printing and optical scanning technology. The Warsaw-based company would also upgrade an incubation center for surgeons interested in introducing a new product, technology or technique.
In one chart: Obamacare exchange has failed to expand coverage in Indiana
For 2014, at least, Obamacare's dreams of expanding individual insurance coverage in Indiana have simply failed. There's no getting around it.
Purdue-based cancer imaging firm lands $15M in funding
OnTarget Laboratories LLC’s technology was developed by Philip Low, a Purdue chemistry professor who also created the technology behind Endocyte Inc.